ARTICLE
27 March 2020

Families First Coronavirus Response Act Mandates Employer-Provided Coverage For COVID-19 Testing

MW
McDermott Will & Emery

Contributor

McDermott Will & Emery logo
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 1,100 lawyers across several office locations worldwide, our team works seamlessly across practices, industries and geographies to deliver highly effective solutions that propel success.
As part of the Families First Coronavirus Response Act (the "Act"), Congress eliminated patient cost-sharing for Coronavirus (COVID-19) diagnostic testing and related services provided under employer-sponsored group health plans.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

As part of the Families First Coronavirus Response Act (the "Act"), Congress eliminated patient cost-sharing for Coronavirus (COVID-19) diagnostic testing and related services provided under employer-sponsored group health plans. This impacts all employer plans, insured and self-funded, of all sizes. The provisions are effective as of March 18 and will continue on a temporary basis for at least 90 days unless extended by the Department Health and Human Services (HHS).

In Depth


Meant to result in zero cost to consumers, the Act mandates that self-funded and fully-insured group health plans (including grandfathered plans) cover all costs (e.g., copayments, coinsurance and deductibles) related to COVID-19 diagnostic testing. This includes items and services provided during:

  • Urgent care center visits,
  • In-person and telehealth visits, and
  • Emergency room visits that result in an order for in vitro diagnostic products approved by the Food and Drug Administration,

but only to the extent such items and services relate to the provision of the diagnostic test or the evaluation of an individual to determine whether a test is necessary. The Act additionally prohibits group health plans from imposing prior authorization or other medical management requirements on any of the foregoing COVID-19 diagnostic testing services.

Though the Act promotes early detection of COVID-19 by relieving patients of diagnostic testing costs that otherwise may have proved prohibitive, as written, its provisions place responsibility on employers for virtually unlimited costs related to COVID-19 testing. This may become particularly onerous for employers where out-of-network testing and treatment are concerned.

The Act does not extend to require coverage of treatment for COVID-19 on a first-dollar basis. However, some fully-insured plans (and other self-funded plans not subject to ERISA) are subject to state mandates that require such coverage for treatment of COVID-19 without cost-sharing to the individual. These state directives and recent guidance by the IRS (Family and Medical Leave Act (FMLA) and sick leave, tax credits, and certain Medicare and Medicaid coverage rules.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More